Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: From basic to practice Review


Authors: Wudhikarn, K.; Park, J. H.
Review Title: Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: From basic to practice
Abstract: Over the past recent years, CD19-targeted chimeric antigen receptor T (CAR T) cell has transformed the treatment of relapsed/refractory (R/R) B lymphoid hematologic malignancy. CAR T cell therapy elicits an excellent anti-tumor effect and extends long-term disease-free remission in these difficult-to-treat patients. Notwithstanding, despite the impressive anti-tumor efficacy, some patients fail to attain clinical response or relapse after extended follow-up. The success of CAR T cell therapy involves complex interplays between host, tumor, and CAR T cell-associated arrays. Researchers have extensively explored potential predictive biomarkers for response to CAR T cell therapy. Ability to identify clinical and biological factors associated with improved response will help determine appropriate patients for CAR T cell treatment and enhance the clinical outcome of this novel therapeutic approach. © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: leukemia; immunotherapy; lymphoma; chimeric antigen receptor t cell (car t cell)
Journal Title: Leukemia and Lymphoma
Volume: 61
Issue: 10
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2020-01-01
Start Page: 2324
End Page: 2334
Language: English
DOI: 10.1080/10428194.2020.1761967
PUBMED: 32522059
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 October 2020 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jae Hong Park
    357 Park